Sustaining the healthcare system requires meticulous evaluation of budgetary implications
Agency officials said this week that they have received reports of problems after patients used versions of semaglutide, the active ingredient in the brand-name medications, which have been compounded, or mixed in pharmacies
In the SUSTAIN clinical trial program evaluating injectable semaglutide for type 2 diabetes, the 1 mg weekly dose reduced HbA1c by approximately 1.41.6% from baseline, while the SUSTAIN FORTE trial showed that the 2 mg dose provided additional glycemic benefits for patients needing intensification
Used Ozempic, Rybelsus, Wegovy or Mounjaro for at least 30 days experienced persistent vomiting for 2 or more weeks have been hospitalized for vomiting and/or gastric complications while either still taking the medication or within 60 days of stopping, and
This can lead to vertigo, often as a result of damage to the structures involved in balance